All times shown are EST.
8:00 am Online Networking
8:45 am Chair’s Opening Remarks
Assessing the Potential of PARP Inhibitors in Combination Therapies to Overcome Resistance Mechanisms
9:00 am The Potential of PARP & ATR Inhibitor Combinations
9:30 am Olaparib in Combination with Other Drugs: Novel Strategies to Overcome Resistance
10:00 am Novel Potent USP1 Inhibitors have Strong Combination Activity with PARP inhibitors and have Complimentary Mechanisms of Resistance
10:30 am A Bespoke Screening Platform to Study Mono(ADP-ribosylation)
Synopsis
- PARP enzymes deposit mono(ADP-ribosylation) or poly(ADP-ribosylation) on their substrate proteins
- Resulting ADP-ribosylation is involved in cellular signaling in processes such as cellular stress response, protein homeostasis and immunology/inflammation
- Developed BEACON+ platform to enable drug discovery for monoPARP enzymes that does not rely on knowledge of the substrates for each enzyme, which are poorly understood
- Screening platform used to develop tool compounds for multiple monoPARP enzymes, including PARP7 inhibitor (RBN-2397) in phase 1 clinical trial in oncology